{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=16", "query": { "condition": "Genetic Change", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1794, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T08:46:00.835Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06496568", "title": "A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PIK3CA-Mutated Cancers" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-12-11", "completion_date": "2027-07-21", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06496568" }, { "nct_id": "NCT04009148", "title": "Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "BRCA-Mutated Ovarian Carcinoma", "BRIP1 Gene Mutation", "MSH2 A636P", "MLH1 Gene Mutation", "MSH6 Gene Mutation", "PMS2 Gene Mutation", "EPCAM", "RAD51C Gene Mutation" ], "interventions": [ { "name": "CASCADE genetic screening", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 118, "start_date": "2019-03-01", "completion_date": "2027-04-23", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04009148" }, { "nct_id": "NCT06440135", "title": "Ziftomenib Maintenance Post Allo-HCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia in Remission", "NPM1 Mutation", "KMT2A Rearrangement" ], "interventions": [ { "name": "Ziftomenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2024-06-11", "completion_date": "2029-04-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Columbus, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06440135" }, { "nct_id": "NCT07341867", "title": "Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Triple Negative Breast Cancer", "Duffy Blood Group, Chemokine Receptor Gene Mutation", "Duffy Blood Group, Chemokine Receptor Gene C.-67T>C" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "LENALIDOMIDE", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andrew Hantel, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2026-07-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07341867" }, { "nct_id": "NCT05759949", "title": "First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "PIK3CA Mutation", "Solid Tumor, Adult", "HER2-negative Breast Cancer", "Breast Cancer", "Metastatic Breast Cancer", "Advanced Breast Cancer", "Unresectable Solid Tumor", "Hormone Receptor Positive Tumor" ], "interventions": [ { "name": "RLY-5836", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Relay Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-03-29", "completion_date": "2025-04-11", "has_results": false, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 7, "location_summary": "Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05759949" }, { "nct_id": "NCT03745326", "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Cancer", "Pancreatic Cancer", "Gastric Cancer", "Colon Cancer", "Rectal Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)", "type": "BIOLOGICAL" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Chest x-ray", "type": "DIAGNOSTIC_TEST" }, { "name": "Photography", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 5, "start_date": "2019-05-16", "completion_date": "2022-08-23", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03745326" }, { "nct_id": "NCT02965378", "title": "Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "FGFR1 Gene Amplification", "FGFR1 Gene Mutation", "FGFR2 Gene Amplification", "FGFR2 Gene Mutation", "FGFR3 Gene Amplification", "FGFR3 Gene Mutation", "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "FGFR Inhibitor AZD4547", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 43, "start_date": "2014-10", "completion_date": "2019-10", "has_results": true, "last_update_posted_date": "2021-05-27", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 1083, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02965378" }, { "nct_id": "NCT02390219", "title": "Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis", "Advanced Lung Disease" ], "interventions": [ { "name": "Lumacaftor", "type": "DRUG" }, { "name": "Ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 46, "start_date": "2015-03", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 6, "location_summary": "Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02390219" }, { "nct_id": "NCT02082665", "title": "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Rosuvastatin10 mg tablet", "type": "DRUG" }, { "name": "Midazolam 3 mg syrup", "type": "DRUG" }, { "name": "Dabrafenib 75 mg capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 6, "start_date": "2015-02-19", "completion_date": "2016-08-01", "has_results": false, "last_update_posted_date": "2017-07-24", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082665" }, { "nct_id": "NCT00909532", "title": "Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 167, "start_date": "2009-06", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-11-12T08:46:00.835Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Oakland, California • Palo Alto, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00909532" } ] }